MEDI:GATE NEWS Bridge Biotherapeutics Begins Administration of Patients in Clinical Participation of BBT-176, a Next-Generation New Lung Cancer Drug Candidate
Bridge Biotherapeutics, an innovative new drug research and development company, announced on the 7th that it was administered to patients who participated in the first phase 1/2 clinical trial of …